HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026
HotSpot Therapeutics, Inc., a biotech firm focused on advancing oral, allosteric small-molecule therapies that engage natural regulatory pockets, has announced plans to share preclinical findings from its interferon regulatory factor 5 (IRF5) research program at the 15th European Lupus Meeting, scheduled for March 4–7, 2026, in Lisbon, Portugal.
Presentation Information:
Title: Preclinical Assessment of IRF5 Small-Molecule Inhibitors Demonstrating Strong Activity in Lupus-Associated Models
Session: Poster Session 11: Emerging Treatments, Including Biologics, Precision Medicines, and Cell-Based Therapies
Date & Time: Friday, March 6 | 7:30–18:15 GMT
Venue: Poster Area
Presentation Information:
Title: Preclinical Assessment of IRF5 Small-Molecule Inhibitors Demonstrating Strong Activity in Lupus-Associated Models
Session: Poster Session 11: Emerging Treatments, Including Biologics, Precision Medicines, and Cell-Based Therapies
Date & Time: Friday, March 6 | 7:30–18:15 GMT
Venue: Poster Area
Companies